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Abstract
Lysosomal exoglycosidases gradually degrade oligosaccharide chains of glycoconjugates 
(glycoproteins, glycolipids, glycosaminoglycans) in cell lysosomes. Defect in the activ-
ity of suitable lysosomal exoglycosidase stops degradation of oligosaccharide chains on 
sugar molecules not released by deficient exoglycosidase, and nondegraded oligosac-
charide chains are stored in enlarged lysosomes. Enlarged lysosomes damage remaining 
cell structures and disturb the function of involved tissues, causing storage diseases. An 
increase in the activity of exoglycosidases in tissues and body fluids is observed in the 
reconstruction of damaged tissues. Exoglycosidase activity is an inexpensive and sensi-
tive marker in diagnostics and monitoring of many diseases.
Keywords: lysosomal exoglycosidases, fucosidase (FUC), β-D-galactosidase (GAL), 
β-D-glucuronidase (GLU), N-acetyl-β-hexosaminidase (HEX), α- and β-mannosidases 
(MAN)
1. Introduction: lysosomes
Inside lysosomes, more than 50 hydrolytic enzymes (glycosidases, proteases, lipases, nucle-
ases, phosphatases, sulfatases, etc.) that are able to degrade all types of cell macromolecules are 
located. Lysosomal enzymes are active at acidic (pH ~5.0) water environment. High intralyso-
somal [H+] (about 100x higher than in cytoplasm) is maintained by vacuolar H+, V-type ATPase, 
located in the lysosomal membrane, which uses the energy of ATP hydrolysis to pump protons 
into lysosomes [1–3]. Lysosomal unique highly acidic environment creates some sort of protec-
tion for cytoplasmic components against noncontrolled autodigestion, additionally reinforced 
by integral proteins of the lysosomal membrane that are highly glycosylated to protect both 
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lysosomal membrane and cytosolic elements against autodigestion [2, 4, 5]. Furthermore, some 
of the membrane glycoproteins function as specific receptors for molecules destined to degra-
dation in lysosomes [3].
Designated for autodigestion, extracellular high-molecular substances reach lysosomes by 
endocytosis, pinocytosis, and phagocytosis [6]. Intracellular high-molecular substances are 
digested by autophagy [7]; autophagy eliminates waste or damaged parts of the living cells. 
There are many types of autophagy: macroautophagy, microautophagy, chaperone-depen-
dent autophagy, and specific autophagy. Autophagy may also be classified according to the 
digested material, e.g., mitophagy (digestion of mitochondria) or nucleophagy (digestion 
of nuclear debris) [8–10]. The best described is macroautophagy, where the cellular region 
destined for digestion is surrounded by the phospholipid membrane creating autophago-
some. Then autophagosome merges with lysosome, where acid hydrolases degrade autosome 
contents into simple organic compounds, ready for utilization by the cell [11]. Additionally, 
autophagy provides the cells with energy [12]. Autophagy may be induced by hypoxia-caused 
stress, hunger, radiation, inflammation, and so on [8]. In the case of pathological autophagy, 
cells exposed to intracellular toxins suffer from defective metabolism and die. Some of the 
researchers suspect that deficient autophagy may initiate many diseases such as diabetes 
or Alzheimer's disease [8], or even cancerogenesis. On the other hand, excessive autophagy 
may facilitate the survival of neoplastic cells during harmful conditions (e.g. chemotherapy). 
Therefore, autophagy in neoplasia may have dual biological sense [13].
2. Lysosomal enzymes
In autophagy, lysosomal acid proteases and glycosidases play a main role. Proteases cleave 
peptide bonds in the middle (endopeptidases) or outside (exopeptidases) of polypeptide 
chains. Main group of lysosomal proteolytic enzymes constitute cathepsins [14, 15], having 
aspartate (cathepsin D and E), cysteine (cathepsins B, C, H, K, and L), or serine (cathep-
sins A and G) in the active site [16, 17]. Proteases (PROT) (Figure 1) facilitate the action of 
three groups of glycosidases that gradually degrade tissue glycoconjugates (glycoproteins, 
glycolipids, and glycosaminoglycans): aminohydrolases that hydrolyze the N-glycosidic 
linkage between amino group of polypeptide chain asparagine and N-acetylglucosamine 
of oligosaccharide chain of glycoprotein, endoglycosidases that hydrolyze O-glycosidic 
bonds inside of oligosaccharide chains, and exoglycosidases that hydrolyze O-glycosidic 
bonds releasing sugars from nonreducing and reducing terminals of oligosaccharide chains 
[18].
Aminohydrolases as well as endo- and exoglycosidases create a sequence of reactions where 
the product of the previous enzyme is the substrate for the subsequent enzyme (Figure 1), 
and oligosaccharide is digested from reducing and nonreducing ends. When neuramini-
dase (NEU) releases N-acetylneuraminic acid (NANA) from the nonreducing ends of oli-
gosaccharide chains, PROT degrade protein cores of glycoproteins, releasing reducing 
ends of oligosaccharides with attached asparagines. Oligosaccharides deprived of NANA 
are substrates for appropriate exoglycosidases depending on oligosaccharide composition. 
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Oligosaccharides with β-D- galactose on non-reducing ends are substrates for β- galac-
tosidase and oligosaccharides with α-L-fucose near reducing ends are substrates for α-L-
fucosidase (Figure 1). Then, oligosaccharide chains are degraded by aspartylglucosaminidase 
(Asp-GlcNAc) that hydrolyses N-glycosidic bond between N-acetylglucosamine of the 
reducing end of oligosaccharide and asparagine remained from polypeptide as well as endo- 
N-acetylglucosaminidase (E-GlcNAc) releasing N-acetyloglucosamine from the reducing end 
Figure 1. A sequential degradation of glycoproteins in lysosomes based on Ref. [19]. Asn—asparagine, Fuc—fucose, 
Gal—galactose, GlcNAc—N-acetylglucosamine, Man—mannose, NANA—N-acetylneuraminic acid, Asp-GlucNAc—
aspartylglucosaminidase, E-GlcNAc—endo N-acetylglucosaminidase, FUC—α-fucosidase, GAL—β-galactosidase, 
HEX—N-acetyl-β-hexosaminidase, MAN—α- and β-mannosidases, NEU—neuraminidase (sialidase), PROT—proteases.
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of oligosaccharide chains. N-acetylhexosaminidase (NAG, N-acetyl-β-hexosaminidase (HEX)) 
releases N-acetyloglucosamine and N-acetylgalactosamine from a nonreducing end of the 
remaining part of oligosaccharide chains. Oligosaccharides containing mannose are substrates 
of α- and β – mannosidases (Figure 1). Lack or deficiency of a particular exoglycosidase blocks 
catabolism of oligosaccharide chains on a nondetached sugar residue [19]. Disorders in the 
activity of lysosomal enzymes are closely related to autophagy and reflect intensity of devel-
opment and course of many diseases, for example, infections, inflammations, cancers, heart 
diseases, Crohn’s disease, myopathy, liver diseases, and neurodegenerations. Autophagy is 
induced in cells by numerous factors: bacterial or viral infections, oxidative stress, and lack 
of nutrients. Some of the literature data also indicate the protective effect of autophagy [8, 
20–23]. Increase in the activity of exoglycosidases in tissues [24–27] and body fluids [28–32] 
is observed in autophagy combined with the reconstruction of damaged tissues. In addition, 
determination of exoglycosidase activity is inexpensive and sensitive [33]. In joint diseases 
(osteoarthritis, rheumatoid arthritis, and Lyme arthritis), progressive destruction of joint car-
tilages occurs. Destruction of cartilage is a multifactorial process caused by concerted action 
of lysosomal hydrolases (Figure 2). Proteases digest polypeptide chains of glycoconjugates 
exposing glycopeptides. Endoglycosidases (hyaluronidases, chondroitinases, keratanases, 
etc.) break down glycosidic bonds inside glycoconjugates and release oligosaccharide chains 
from the protein core. Lysosomal exoglycosidases, HEX, GAL, β-D-glucuronidase (GLU), and 
so on, release monosaccharides from the nonreducing terminals of oligosaccharide chains of 
glycoproteins, glycolipids, and glycosaminoglycans of synovial tissue, articular cartilage, and 
synovial fluid (Figure 2) [34].
2.1. Lysosomal exoglycosidases
Lysosomal exoglycosidases include GAL, GLU, FUC, HEX, as well as MAN. Among lyso-
somal exoglycosidases, the most active is HEX [35] that releases N-acetyloglucosamine and 
Figure 2. Cartilage destruction by proteases and glycosidases based on [34]. GAG—glycosaminoglycans, GAL—β-galac-
tosidase, GLU—β-glucuronidase, and HEX—β-hexosaminidase.
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N-acetylgalactosamine from nonreducing ends of oligosaccharide chains of glycoconjugates 
(glycoproteins, glycolipids, and glycosaminoglycans). HEX is a glycoprotein composed of 
two (α and β) subunits. HEX subunits create three isoenzymes: HEX A (αβ), HEX B (ββ), 
and HEX S (αα) [36]. Predominant are HEX A and HEX B present in different proportions 
in the particular tissue [19]. Higher concentration of HEX A in comparison to HEX B may 
be connected with selective degradation of glycosaminoglycans, because HEX A releases 
N-acetylhexosamines from acid oligosaccharide chains. Some glycolipids (e.g., gangliosides 
GM2 and GA2) also are degraded exclusively by HEX A. HEX A is thermolabile and under-
goes inactivation at pH ~5 after 3 h of incubation at 50°C. Such conditions does not change 
the activity of HEX B significantly and thus thermal inactivation is used for the differential 
determination of HEX A and HEX B in biological materials [37].
Human FUC is a glycoprotein occurring in different molecular forms. During separation on 
Sephadex G-200 column, FUC is eluted in two peaks: α-L-fucosidase I and α-L-fucosidase II. 
Both isoforms of α-L-fucosidase differ in molecular mass, pH optimum, and susceptibility on 
heat denaturation (both isoforms are thermolabile, but α-L-fucosidase I undergoes thermal 
inactivation in basic environment) [38].
Human GAL possesses three isoenzymes: A, B, and C (GAL C activity is small). Isoenzymes A 
and B absorb at 95% on concanavaline A (ConA) column, and at 60% on wheat germ aggluti-
nin (WGA) column. Absorbance on ConA indicates the presence of mannose, and absorbance 
on WGA indicates the presence of N-acetylgalactosamine and N-acetylglucosamine in oligo-
saccharide chains of GAL [39].
Human MAN has three isoenzymes: A, B, and B2 that differ in sialic acid content and spa-
tial arrangement of atoms in macromolecules [40]. Human GLU is a tetrameric glycoprotein 
with MW 310–380 kDa. In humans, there are two forms of β-D-glucuronidase: endogenic and 
exogenic (bacterial GLU derived from intestinal bacteria: Escherichia coli, Peptostreptococcus, 
Bacteroides, Clostridia) [41, 42]. Increase in the activity of bacterial β-D-glucuronidase in gas-
trointestinal tract increases detoxication by hydrolysis of glucuronides combined with drugs 
and other toxic substances, secreted with bile [43, 44]. It was reported that the activity of bac-
terial β-D-glucuronidase in gastrointestinal tract of persons on high meat diet is significantly 
higher than that in persons on vegetarian diet [45].
2.1.1. Decrease in the activities of lysosomal exoglycosidases
Both deficiency and excessive HEX activity may have clinical significance. Inherited deficiency 
in HEX A (Tay-Sachs disease) causes storage of nondigested ganglioside GM2 in lysosomes of 
the neural cells. Enlarged lysosomes oppress remaining organelles of neurons that undergo 
apoptosis [46]. Up to 5–6 months of life, infants with Tay-Sachs disease develop normally but 
eventually show impairment of vision, hearing, and movement as well as growing mental 
retardation. Tay-Sachs children usually live up to 4–5 years of age [35]. Tay-Sachs disease 
may (but much less often) occur in teenagers and adults, generating milder symptoms [47]. 
Crucial for the diagnosis of Tay-Sachs disease is the significant decrease in HEX A activity in 
blood serum, leukocytes, and skin fibroblasts. Tay-Sachs disease may be diagnosed during 
pregnancy by determination of HEX A activity in amniotic fluid [35].
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Deficit in HEX A and HEX B activity induces Sandhoff’s disease that has symptoms similar to 
Tay-Sachs disease, with additional storage of oligosaccharides in internal organs, mainly liver 
and spleen. Children with Sandhoff’s disease also live up to 4–5years of age [35]. Sandhoff’s 
disease may appear in older children and adolescents as well as adults, but in older people it 
occurs extremely rarely. Symptoms of Sandhoff’s disease in older children, adolescents, and 
adults are unspecific and include muscular weakness, lack of motoric coordination (ataxia), 
speech disorders, and mental retardation. For confirmation of Sandhoff’s disease, determina-
tion of HEX in blood serum, leukocytes, tears, and skin fibroblasts of potential patients is 
recommended [35].
Absence or deficiency of α-L-fucosidase leads to mucopolysacharydosis, called fucosidosis. 
Fucosidosis is characterized by lysosomal storage of glycoproteins, glycolipids, and oligosaccha-
rides containing fucose residues. Fucosidosis may be confirmed by the decrease in α-L-fucosidase 
activity, in fibroblasts or leukocytes of suspected persons [35].
Decreased activity of α-L-fucosidase in breast tissue may be a predisposing factor for the 
appearance of breast cancer, because high levels of cell surface-associated α-L-fucose are 
related to neoplastic progression [48].
Deficiency of β-D-galactosidase results in generalized gangliosidosis with lysosomal stor-
age of keratan sulfate, oligosaccharide chains of glycoproteins, and gangliosides GM1. 
Generalized gangliosidosis is manifested by mental retardation, liver enlargement, and bone 
deformation. Absence of GAL leads to Krabbe disease with storage of galactosyloceramide 
[35]. Deficiency of α-L-mannosidase (mannosidosis) is characterized by primary immune 
deficiency, skeletal abnormalities, facial dysmorphy, and mental retardation [49]. An inher-
ited lack of β-D-glucuronidase activity results in metabolic disease called Sly syndrome or 
mucopolysaccharidosis VII. Sly syndrome may cause generalized edema of fetus before deliv-
ery. Fetuses that survive generalized edema before delivery frequently suffer from mental 
retardation, littleness, thick facial features, as well as liver and spleen enlargement [35].
2.1.2. Increase in lysosomal exoglycosidase activities
Intensive inflammatory processes, for example tonsillitis, usually are accompanied by increase 
in lysosomal glycoconjugate catabolism [50]. Hashimoto et al. [51] reported that pancreatic 
inflammation increases autophagy in the pancreatic inflamed cells. During autophagy, there 
is observed increase in the activity of lysosomal enzymes characteristic to the involved tis-
sue. The most active of lysosomal exoglycosidases is HEX. Therefore, HEX activity in tissues 
and body fluids is particularly sensitive and is a specific diagnostic parameter for diseases 
proceeding with increased glycoconjugate degradation. HEX in serum and its isoenzyme B 
(HEX B) in urine became sensitive and specific markers of alcoholic abuse [52, 53]. A signifi-
cant increase in serum HEX A activity in smokers may be a marker of risk for arteriosclerosis 
[54], and an increased HEX A in saliva may be a marker of periodontitis in persons addicted 
to ethanol [28]. In infectious diseases (e.g., Lyme arthritis), a significant increase in the activity 
of lysosomal exoglycosidases (including HEX) in serum [55] and synovial fluid was observed 
[30]. In chronic exposition of rats to cadmium, damage to the proximal renal canalicules and 
significant increase in HEX and HEX A activities in urine of exposed rats were observed [29].
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Determination of HEX in neoplastic tissues presents ambiguous results that depend on cir-
cumstances [56]. Generally, in cancerous tissue, increase in the activity of hydrolytic enzymes 
including HEX should be observed. In tissues of benign neoplasm of human salivary gland a 
significant increase in HEX and its isoenzymes was observed, in comparison to healthy sali-
vary gland [57]. A significant increase in the activity of lysosomal enzymes (including HEX, 
HEX A, and HEX B) was reported in malignant brain tissue in comparison to brain tissues 
without neoplastic changes [58]. But also significant decrease in HEX, HEX A, and HEX B 
activities in renal cancer tissue in comparison to healthy renal tissue was reported, followed 
by a significant increase in HEX and its isoenzymes in urine of neoplastic patients in com-
parison to healthy persons [27]. Therefore, determination of urinary HEX and its isoenzymes 
may be particularly useful in diagnostics of neoplasms derived from renal epithelial cells of 
proximal contorted canalicules. Activity of urinary HEX and other exoglycosidases may be 
helpful in the diagnostics of pancreatic [31] and colon [32] cancers. Detection of HEX and its 
isoenzyme activity in stools may be used in elaboration of screening markers for detection of 
the colon cancer [59]. Determination of HEX activity in serum and saliva may be used for the 
diagnostics and control of salivary gland tumors [25]. The activity of lysosomal α-L-fucosidase 
(FUC) [60] reflects the intensity of degradation the α-L-fucose containing glycoproteins and 
glycolipids [25]. The activity of β- galactosidase (GAL) reflects intensity of degradation gly-
coproteins, glycolipids and glycosaminoglycans containing galactose [39] and activity of 
β-glucuronidase (GLU) reflects intensity of glycosaminoglycans catabolism [61, 62].
Determination of the activities of FUC, GAL, and GLU may be applied for the diagnostics and 
monitoring of diseases proceeding with an increase in catabolism of oligosaccharide chains 
containing sugars released by appropriate exoglycosidases [33]. Increase in the activity of 
α-L-fucosidase in patients with liver cirrhosis seems to be a promising marker for detecting 
small focuses of liver cancer, particularly when currently used markers (α-fetoprotein and 
des-γ-carboxy-prothrombin) seem to be less useful than it was primarily expected [63–66]. 
In the case of β-D-galactosidase, there are suggestions that increase in serum GAL activity 
that may be applied for the diagnostics of glandular colon cancer [59] and larynx cancer [67]. 
Serum β-D-glucuronidase may be a useful marker for recurrence of liver inflammation [68] 
and increase in proteoglycans degradation in diabetes [69]. Increased activity of serum and 
tissues β-D-glucuronidase was found in joint inflammation, dermatoses, liver diseases, AIDS, 
and breast, stomach, rectum, and pancreatic cancers [70].
Activities of the lysosomal exoglycosidases in body fluids are good markers of neoplasms, 
inflammations, and infections. Determination of exoglycosidase activities in tissues may be 
helpful in establishing pathogenesis and treatment of some diseases, for example, nasal pol-
yps. Nasal polyps are grape-shaped smooth structures, arising from the inflammatory nasal 
mucous membrane. Nasal polyps bulge to interior of the nose, restricting nasal patency [71]. 
There are different pathogenesis theories of nasal polyps, however, none was satisfactorily con-
firmed, and the lack of understanding nasal polyp pathogenesis impedes therapy. It is known 
that untreated nasal polyps may cause intra- and extracranial complications. Currently used 
pharmacological and surgical treatments of nasal polyps do not provide satisfactory results 
[72]. In nasal polyp tissue, a significant decrease in the concentration of activities of particular 
exoglycosidases was found in comparison to control, with simultaneous increase in specific 
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activity of HEX A [73, 74]. A decrease in concentration of lysosomal exoglycosidases in nasal 
polyp tissue, without significant changes in their specific activities, denies the theory of full 
symptomatic inflammation in nasal polyp pathogenesis and may indicate neoplastic theory.
The activities of lysosomal exoglycosidases may be helpful in the selection of a proper method for 
treatment of hypertrophied and inflammatory palatal tonsils. Healthy palatal tonsils are important 
elements of immunological barrier against infections of the respiratory tracts [75, 76]. In the case of 
hypertrophy of lymphoidal tissue or chronic inflammation of palatal tonsils, otorhinolaryngolo-
gists very often face situations where palatal tonsils fail to serve as an immunological barrier and 
cause complications such as: impeded breathing and swallowing as well as speech disturbance. 
Palatal tonsils hypertrophy and inflammation are indication for tonsillotomy (trimming) or ton-
sillectomy (removal of palatal tonsils) [77, 78]. However, some otorhinolaryngologists claim that 
indications for tonsillo- and tonsillectomy should be limited, especially in younger children (6–7 
years old), because the role of palatine tonsils and the possibility of surgical complications are not 
fully known [77–79]. Popko et al. [80] reported that the activity of lysosomal exoglycosidases in 
palate tonsils is independent of patients' age and she concluded that probably chronic inflamma-
tory processes of the connective tissue of palate tonsils have the same intensity in childhood and 
in mature persons, and therefore she recommend tonsillectomy even in childhood.
3. Preparation of tissues and body fluids for determination of lysosomal 
exoglycosidases
Tissues for exoglycosidase determination were collected during surgery, rinsed in tap water, 
and then in 0.9% saline. After drying with sterile swab, the tissue was weighed, suspended 
in 0.154-M KCl with 0.2% Triton X-100 (9 mL of fluid for 1 g of tissue) and homogenized. The 
homogenate was centrifuged at 40C for 20 min at 12.000 xg. The supernatants were used to 
determine exoglycosidase activity [25, 72].
Cell culture: Isolated tissue was cut into small pieces (about 0.5 mm2) and incubated in a mix-
ture prepared in the following proportions: 1.5 mg of collagenase (Clostridium histolyticum type 
I-A) and 1 mg of hyaluronidase in 1 mL of DMEM (Dulbecco’s modified Eagle’s medium), for 
1–2 hours at a temperature of 37°C. After incubation the cells were centrifuged and washed 
with medium (DMEM), the rinsed cells were then cultivated in plastic bottles (25-cm2 culture 
surface) on DMEM with: 10% of calf serum in 25-mM Hepes buffer, 10,000-U/mL penicillin, 
and 1-mg/mL streptomycin, at 37°C and an atmosphere saturated with 5% CO
2
 for –3–5 days, 
when cells grow up to ~80% of confluence [80].
Articular fluid was collected with sterile syringe needle during local anesthesia, usually at 
USG control. Collected articular fluid was centrifuged, and exoglycosidases were determined 
in the supernatant [62].
Urine collection from midstream (after night and after hygiene of intimate places) for deter-
mination of exoglycosidases was performed at the same way as for general examination of 
urine. Exoglycosidase activity determination was performed in supernatants from centri-
fuged urine [32].
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Saliva secreted to the bottom of the oral cavity was spitted off to the plastic containers placed 
in crushed ice and then centrifuged; salivary exoglycosidases were determined in the super-
natant [74].
Plasma: Blood was collected typically to anticoagulant from cubital vein and then centrifuged 
for 5 min at 4000 rev/min. Plasma was collected in plastic tubes [81].
Serum: Blood was taken typically from cubital vein, without an anticoagulant. After clot-
ting in room temperature (30–60 min), the clot was centrifuged off at 4000 rev/min for 5 min. 
Serum was collected in plastic tubes [82].
Tissues immediately after resection, rinsing, and drying were frozen and stored at −80°C 
for a very long time. In homogenates and supernatant fluids, exoglycosidases should be 
determined without delay. Synovial fluids, urine, saliva, plasma, and serum may be stored 
at −80°C.
Determination of lysosomal exoglycosidases is usually performed by modifications of the 
Chatterjee et al. [83] method based on incubation of suitable tissue homogenates or body flu-
ids with 4-nitro-derivatives of adequate sugar as substrates, in buffered incubation mixture 
of appropriate pH (4.7 for HEX, 4.5 for GLU, and 4.3 for GAL, FUC, and MAN), at optimal 
temperature (36°C), and optimal incubation time (60 min). Enzymatic reaction is terminated 
by alkalization of the incubation mixture (usually by borate buffer at pH 9.8). Chatterjee et al. 
[83] method was adopted for the determination of exoglycosidases in synovial fluid [62] and 
saliva [74]. Recently we have published the method for determination HEX [82] in serum from 
hemolyzed blood  (Figure 3) [84].
4. Conclusion
The above literature review indicates the activities of lysosomal exoglycosidases in tissues 
and body fluids as the markers for detection and monitoring of many human diseases.
Figure 3. (HEX) determination in the serum of hemolyzed (upper part) and nonhemolyzed blood (lower part). Reprinted 
from [82], with permission from Elsevier: order number: 4042581223257. TCA—trichloroacetic acid.
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